Torrey Pines Institute’s Board Appoints Dr. Gregory S. Welmaker as President

October 12, 2017

The Torrey Pines Institute for Molecular Studies (TPIMS) Board of Trustees has appointed Gregory S. Welmaker, Ph.D., M.B.A. to the position of President of the not-for-profit research organization. Dr. Welmaker has served as the Chief Operating Officer of TPIMS since October 20, 2014, after joining TPIMS in February 2010. In 2011, he took on the role as Director of Drug Discovery. While at TPIMS, Dr. Welmaker has managed TPIMS’ Florida Drug Discovery Acceleration Program, a program supported by the State of Florida to enhance translational research within the state. In two years, under Dr. Welmaker’s direction, the program collaborated with 50 principal researchers at 15 institutes throughout Florida and has filed 6 patents and generated over $10 million in federal funding to support their ongoing programs. Dr. Welmaker is currently a co-Principal Investigator, with Dr. Richard A. Houghten, on the National Cancer Institute’s Experimental Therapeutics (NExT) Program. TPIMS is the only Florida institute to have been selected to work within the NExT Program. Dr. Richard A. Houghten, CEO & Founder of TPIMS, congratulates Dr. Welmaker on this appointment and shared his optimism of TPIMS’ future under the continued and expanded leadership of Dr. Welmaker, “He has been a driving force to further the technologies developed at TPIMS and I am pleased and honored that Greg has accepted the title of President & Chief Operating Officer. He is definitely the right man at the right time for this promotion.”

TPIMS’ Chairman Dr. Robin Offord said, “TPIMS’ Board of Trustees is proud of Dr. Welmaker’s achievements and we know that there are many more to come. We count ourselves fortunate to have him in such a key role”.

Prior to joining TPIMS, Dr. Welmaker spent 14 years as a Principal Scientist at Wyeth Research (now Pfizer) in Princeton, NJ and Collegeville, PA. During this time, he had the opportunity to lead both discovery teams (aimed at identifying Investigational New Drug (IND) candidates) and exploratory teams (aimed at defining and validating new research programs). Prior to joining Wyeth, he worked at Ariad Pharmaceuticals in Cambridge, MA. Dr. Welmaker received his PhD in organic chemistry in 1992 and then completed an American Cancer Society Postdoctoral Fellowship from 1993-1994. In 2009, Greg received an MBA in Pharmaceutical Management.


Torrey Pines Institute for Molecular Studies is a 501(c)(3) organization with research centers in Port St. Lucie, FL and San Diego, CA. Scientists conduct research in fields associated with a wide variety of major medical conditions, including multiple sclerosis, cancer, heart disease, Types I and II diabetes, macular degeneration, pain management, Alzheimer's, inflammatory disorders, AIDS and other infectious diseases, regenerative medicine, obesity, transplant rejection, muscle wasting syndrome, rheumatoid arthritis and new methods for drug discovery.

Torrey Pines Institute for Molecular Studies
This email address is being protected from spambots. You need JavaScript enabled to view it.
11350 SW Village Pkwy
Port St. Lucie, FL 34987
Phone: (772) 345-4587